Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9332942 | 0.98 | APP (0.59) | APPCA1CA2CA7CA9 | |
| SCHEMBL28842576 | 0.94 | MCHR1 (0.55) | APPCA1CA2CA7CA9 | |
| SCHEMBL14085288 | 0.83 | APP (0.52) | APPCA1CA2CA7CA9 | |
| SCHEMBL8213728 | 0.83 | CYP1A2 (0.47) | APPCA1CA2CA7CA9 | |
| SCHEMBL20681007 | 0.82 | HAO1 (0.40) | APPMCHR1HAO1ACACB | |
| SCHEMBL9333484 | 0.82 | APP (0.55) | APPCA1CA2CA7CA9 | |
| SCHEMBL10300057 | 0.81 | APP (0.77) | APPCA1CA2CA7CA9 | |
| SCHEMBL674764 | 0.81 | APP (0.77) | APPCA1CA2CA7CA9 | |
| SCHEMBL9834499 | 0.81 | APP (0.53) | APPCA1CA2CA7CA9 | |
| SCHEMBL7573542 | 0.81 | APP (0.59) | APPCA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11525123-B2 | Diverse carbene transferase enzyme catalysts derived from a P450 enzyme | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210292718-A1 | DIVERSE CARBENE TRANSFERASE ENZYME CATALYSTS DERIVED FROM A P450 ENZYME | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-09-23 | — | — | US | disclosed |
| US-9580425-B2 | Pyrido[3,4-b] indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150352087-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-12-10 | — | — | US | disclosed |
| CN-102491969-B | Heteroaromatic quinoline compounds and the purposes as PDE10 inhibitor thereof | PFIZER PRODUCTS INC. (US) | 2015-08-19 | — | — | CN | disclosed |
| US-9045482-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150005322-A1 | PYRIDO[3,4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8859561-B2 | Pyrido[4,3-b]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| CN-101098866-A | Heteroaromatic quinoline compounds and their use as pde10 inhibitors | PFIZER (US) | 2008-01-02 | — | — | CN | disclosed |
| CN-101087786-A | Heterocyclic carbamate derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | CN | disclosed |
| CN-101087787-A | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | CN | disclosed |
| CN-1882586-A | 1H-imidazo[4,5-C]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2006-12-20 | — | — | CN | disclosed |
| CN-1798721-A | Cyclohexyl derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-07-05 | — | — | CN | disclosed |
| CN-1147486-C | 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles | - | 2004-04-28 | — | — | CN | disclosed |
| CN-1418193-A | heterocyclic side chain containing metalloprotease inbibitors | PROCTER & GAMBLE (US) | 2003-05-14 | — | — | CN | disclosed |
| CN-1379762-A | Beta substituted metalloprotease inhibitors | PROCTER & GAMBLE (US) | 2002-11-13 | — | — | CN | disclosed |
| CN-1349498-A | Alkenyl-and alkynyl-containing metalloprotease inhibitors | PROCTER & GAMBLE (US) | 2002-05-15 | — | — | CN | disclosed |
| CN-1135515-A | Liquid crystal alkynyl tolane compound, liquid crystal composition and liquid crystal display part | CHISSO CORP (JP) | 1996-11-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005322-A1 | PYRIDO[3,4-B] INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | APP 360/4885CA1 1688/4885CA2 3584/4885 |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | APP 365/4885CA1 1735/4885CA2 3625/4885 |
| US-20150352087-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | APP 365/4885CA1 1735/4885CA2 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.